英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
marinus查看　marinus　在百度字典中的解释百度英翻中〔查看〕
marinus查看　marinus　在Google字典中的解释Google英翻中〔查看〕
marinus查看　marinus　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Marinus Pharmaceuticals, Inc. - Immedica to Acquire Biopharmaceutical . . .
    Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger The
  • Marinus Pharmaceuticals, Inc. - News
    Download , Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results, November 12, 2024, (opens in new window)
  • Marinus Pharmaceuticals Provides Business Update and Reports Fourth . . .
    RADNOR, Pa -- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023 “We are thrilled to announce we have exceeded the enrollment threshold required to conduct an
  • Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals Announces FDA . . .
    About Marinus Pharmaceuticals Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders Ganaxolone is a neuroactive steroid GABA A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects
  • Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial . . .
    About Marinus Pharmaceuticals Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders
  • Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for . . .
    Marinus Pharmaceuticals , Inc (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U S Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut syndrome (LGS) This designation applies to the active moiety of ganaxolone and is
  • Marinus Pharmaceuticals Provides Business Update and Reports Third . . .
    RADNOR, Pa -- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024 “We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on
  • Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC . . .
    RADNOR, Pa -- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults did not meet the primary
  • Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and . . .
    RADNOR, Pa -- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status
  • Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial . . .
    RADNOR, Pa -- (BUSINESS WIRE)-- Marinus Pharmaceuticals , Inc (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Company’s development program for ZTALMY ® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead





中文字典-英文字典  2005-2009